Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 10, 2015, Pages 1182-1191

  Chen, Y C ^a   Peng, C Y ^b   Jeng, W J ^a   Chien, R N ^c   Liaw, Y F ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADULT; ARTICLE; CANCER INCIDENCE; CHRONIC HEPATITIS B; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEPATITIS B VIRUS; HUMAN; INCIDENCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION; VIRUS INHIBITION; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; IMMUNOLOGY; LIVER NEOPLASMS; MIDDLE AGED;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84943665286     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13409     Document Type: Article

References (38)

1. Liaw YF, Lin DY, Chen TJ, Chu CM,. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9: 235-41.
2. Beasley RP,. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-56.
3. Chen CJ, Yang HI, Su J, et al,.; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
4. Chen YC, Chu CM, Liaw YF,. Age-specific prognosis following HBeAg seroconversion in chronic hepatitis B. Hepatology 2010; 51: 435-44.
5. Chu CM, Liaw YF,. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006; 26: 142-52.
6. Chen YC, Chu CM, Yeh CT, Liaw YF,. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007; 1: 267-73.
7. Fattovich G, Bortolotti F, Donato F,. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52.
8. Liaw YF, Sung JJ, Chow WC, et al,. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
9. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL,. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-77.
10. Liaw YF,. Impact of therapy on the long term outcome of chronic hepatitis B. Clin Liver Dis 2013; 17: 413-23.
11. Lok A, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
12. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
13. Liaw YF, Kao JH, Piratvisuth T, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61.
14. Hosaka T, Suzuki F, Kobayashi M, et al,. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
15. Wong GL, Chan HL, Mak CW, et al,. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58: 1537-47.
16. Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW,. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 2014; 109: 1223-33.
17. Arends P, Sonneveld MJ, Zoutendijk R, et al,. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut 2015; 64: 1289-95.
18. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P,. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62: 956-67.
19. Jeng WJ, Sheen IS, Chen YC, et al,. Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients. Hepatology 2013; 58: 1888-96.
20. Sohn HR, Min BY, Song JC, et al,. Off-treatment virologic relapse and outcomes of retreatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis 2014; 14: 439.
21. Chang TT, Liaw YF, Wu SS, et al,. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
22. Marcellin P, Gane E, Buti M, et al,. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.
23. Kumada T, Toyoda H, Tada T, et al,. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013; 58: 427-33.
24. Austin PC,. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J 2009; 51: 171-84.
25. Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF,. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993; 21: 303-8.
26. Liaw YF, Tai DI, Chu CM, et al,. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. Gastroenterology 1986; 90: 263-7.
27. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
28. Singal AK, Salameh H, Kuo YF, Fontana RJ,. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38: 98-106.
29. Chi H, Hansen BE, Yim C, et al,. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther 2015; 41: 867-76.
30. Schiff E, Simsek H, Lee WM, et al,. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776-83.
31. Yokosuka O, Takaguchi K, Fujioka S, et al,. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010; 52: 791-9.
32. Marcellin P, Asselah T,. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol 2013; 28: 912-23.
33. Patwardhan VR, Sengupta N, Bonder A, Lau D, Afdhal NH,. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. Aliment Pharmacol Ther 2014; 40: 804-10.
34. Chang ML, Liaw YF, Hadziyannis SJ,. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2015; 42: 243-57.
35. Liaw YF,. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009; 51: 403-10.
36. Lim SG, Aung MO, Chung SW, Soon CS, Mak BH, Lee KH,. Patient preferences for hepatitis B therapy. Antivir Ther 2013; 18: 663-70.
37. Arama V, Leblebicioglu H, Simon K, et al,. Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. Antivir Ther 2014; 19: 245-57.
38. Chu CM, Lin CC, Chen YC, Jeng WJ, Lin SM, Liaw YF,. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. Br J Cancer 2012; 107: 2010-5.